{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:45:48Z","timestamp":1782722748597,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Homozygous 9p21 deletions are the major cause for MTAP deficiency, making cancer cells more vulnerable towards drugs targeting various pathways. This study aimed to assess the prevalence of heterozygous and homozygous 9p21 deletions in cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A tissue microarray containing 7,172 samples from 125 different tumor entities was analyzed by fluorescence in situ hybridization. This method allows the detection of deletions within single tumor cells, while admixted non-neoplastic cells are omitted. Consecutive sections were immunostained for MTAP and p16 (\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 4,999 evaluable tumors, 10.7% had heterozygous and 7.4% homozygous deletions, which occurred in different tumor categories. Homozygous deletions were most frequent in mesothelioma (up to 47.8%), pancreatic ductal adenocarcinoma (44.7%), and urothelial carcinoma (up to 36.4%) while heterozygous deletions predominated in squamous cell carcinoma (up to 34.3%), leiomyosarcoma (31.4%), and esophageal adenocarcinoma (30.8%). The proportion of homozygous 9p21 deletions was high in mesothelioma (up to 91.6%), urothelial carcinoma (up to 80.0%), and pancreatic ductal adenocarcinoma (76.4%), intermediate in squamous cell carcinomas of different organs (12.5\u201350.0%) and pulmonary adenocarcinoma (46.3%), and low in endometrioid (9.1%) and high-grade serous (4.0%) ovarian carcinoma. MTAP and p16 immunostaining was absent in homozygous 9p21 deletions, while heterozygously deleted cancers showed markedly decreased MTAP immunostaining (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), with unchanged p16 staining.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data provide a comprehensive overview on the prevalence on homozygous and heterozygous 9p21 deletions in cancer and demonstrate that different cancer types markedly differ in their ratio of homozygous\/heterozygous 9p21 deletions. The strong concordance between homozygous 9p21 deletions and absent MTAP immunostaining highlights the effectiveness of immunohistochemistry in detecting MTAP deficiency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-026-01542-0","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:58:19Z","timestamp":1782712699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of heterozygous and homozygous 9p21 deletions in human cancer: a tissue microarray study on 4,999 tumors from 125 different tumor types"],"prefix":"10.1186","volume":"32","author":[{"given":"Natalia","family":"Gorbokon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Teljuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Schraps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Lennartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian Dwertmann","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Reiswich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Viehweger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fraune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M","family":"Luebke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Menz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Schlichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Krech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hinsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Burandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-4258","authenticated-orcid":false,"given":"Ronald","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lebok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Minner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till S","family":"Clauditz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Hackert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faik G.","family":"Uzunoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bernreuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"1542_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer. EBioMedicine. 2016;8:30\u20139.","journal-title":"EBioMedicine"},{"issue":"7283","key":"1542_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899\u2013905.","journal-title":"Nature"},{"issue":"7793","key":"1542_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"ITP-CAWG Consortium","year":"2020","unstructured":"Consortium ITP-CAWG. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82\u201393.","journal-title":"Nature"},{"key":"1542_CR4","doi-asserted-by":"crossref","unstructured":"Harrison PW, Amode MR, Austine-Orimoloye O, Azov AG, Barba M, Barnes I et al. Ensembl 2024. Nucleic Acids Res. 2023; 52 (D1):D891-D899.","DOI":"10.1093\/nar\/gkad1049"},{"issue":"26","key":"1542_CR5","doi-asserted-by":"publisher","first-page":"12324","DOI":"10.1016\/S0021-9258(18)67242-4","volume":"261","author":"F Della Ragione","year":"1986","unstructured":"Della Ragione F, Carteni-Farina M, Gragnaniello V, Schettino MI, Zappia V. Purification and characterization of 5\u2019-deoxy-5\u2019-methylthioadenosine phosphorylase from human placenta. J Biol Chem. 1986;261(26):12324\u20139.","journal-title":"J Biol Chem"},{"issue":"1","key":"1542_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","volume":"13","author":"O Alhalabi","year":"2022","unstructured":"Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, et al. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022;13(1):1797.","journal-title":"Nat Commun"},{"key":"1542_CR7","doi-asserted-by":"publisher","first-page":"1264785","DOI":"10.3389\/fonc.2023.1264785","volume":"13","author":"C Bray","year":"2023","unstructured":"Bray C, Balcells C, McNeish IA, Keun HC. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality. Front Oncol. 2023;13:1264785.","journal-title":"Front Oncol"},{"issue":"1","key":"1542_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","volume":"65","author":"RS Blanc","year":"2017","unstructured":"Blanc RS, Richard S. Arginine Methylation: The Coming of Age. Mol Cell. 2017;65(1):8\u201324.","journal-title":"Mol Cell"},{"issue":"4","key":"1542_CR9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1152\/physrev.00047.2011","volume":"92","author":"SC Lu","year":"2012","unstructured":"Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012;92(4):1515\u201342.","journal-title":"Physiol Rev"},{"issue":"8","key":"1542_CR10","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1073\/pnas.1510959113","volume":"113","author":"B Murray","year":"2016","unstructured":"Murray B, Antonyuk SV, Marina A, Lu SC, Mato JM, Hasnain SS, et al. Crystallography captures catalytic steps in human methionine adenosyltransferase enzymes. Proc Natl Acad Sci U S A. 2016;113(8):2104\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6278","key":"1542_CR11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214\u20138.","journal-title":"Science"},{"issue":"11","key":"1542_CR12","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, et al. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer Discov. 2023;13(11):2412\u201331.","journal-title":"Cancer Discov"},{"key":"1542_CR13","doi-asserted-by":"crossref","unstructured":"Herzberg B, Johnson M. CG K. Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor in MTAP deleted non-small cell lung cancer and urothelial cancer. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; Barcelona, Spain, October 23\u201325, 2024, Abstract LBA501.","DOI":"10.1016\/j.ejca.2024.114979"},{"issue":"10","key":"1542_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/PAS.0000000000002297","volume":"48","author":"N Gorbokon","year":"2024","unstructured":"Gorbokon N, Wossner N, Lennartz M, Dwertmann Rico S, Kind S, Reiswich V, et al. Prevalence of S-methyl-5\u2019-thioadenosine Phosphorylase (MTAP) Deficiency in Human Cancer: A Tissue Microarray Study on 13,067 Tumors From 149 Different Tumor Types. Am J Surg Pathol. 2024;48(10):1245\u201358.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"1542_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1309\/AJCPOATJ9L4GCGDA","volume":"143","author":"T Ito","year":"2015","unstructured":"Ito T, Hamasaki M, Matsumoto S, Hiroshima K, Tsujimura T, Kawai T, et al. p16\/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer. Am J Clin Pathol. 2015;143(6):830\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"1542_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/cncr.23413","volume":"114","author":"FB Onofre","year":"2008","unstructured":"Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Bocking A. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer. 2008;114(3):204\u201315.","journal-title":"Cancer"},{"issue":"1","key":"1542_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0002-9440(10)65105-X","volume":"155","author":"I Orlow","year":"1999","unstructured":"Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol. 1999;155(1):105\u201313.","journal-title":"Am J Pathol"},{"issue":"2","key":"1542_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jss.2007.01.012","volume":"143","author":"R Bartoletti","year":"2007","unstructured":"Bartoletti R, Cai T, Nesi G, Roberta Girardi L, Baroni G, Dal Canto M. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res. 2007;143(2):422\u20137.","journal-title":"J Surg Res"},{"key":"1542_CR19","doi-asserted-by":"publisher","first-page":"435983","DOI":"10.1155\/2014\/435983","volume":"2014","author":"A Puiggros","year":"2014","unstructured":"Puiggros A, Blanco G, Espinet B. Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int. 2014;2014:435983.","journal-title":"Biomed Res Int"},{"issue":"8","key":"1542_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/modpathol.2016.88","volume":"29","author":"TL Lotan","year":"2016","unstructured":"Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, et al. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol. 2016;29(8):904\u201314.","journal-title":"Mod Pathol"},{"issue":"2","key":"1542_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ajpath.2012.04.026","volume":"181","author":"A Krohn","year":"2012","unstructured":"Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012;181(2):401\u201312.","journal-title":"Am J Pathol"},{"issue":"1","key":"1542_CR22","doi-asserted-by":"publisher","first-page":"e70012","DOI":"10.1002\/2056-4538.70012","volume":"11","author":"N Gorbokon","year":"2025","unstructured":"Gorbokon N, Wossner N, Ahlburg V, Plage H, Hofbauer S, Furlano K, et al. Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer. J Pathol Clin Res. 2025;11(1):e70012.","journal-title":"J Pathol Clin Res"},{"issue":"7","key":"1542_CR23","doi-asserted-by":"publisher","first-page":"e0262877","DOI":"10.1371\/journal.pone.0262877","volume":"17","author":"N De Wispelaere","year":"2022","unstructured":"De Wispelaere N, Rico SD, Bauer M, Luebke AM, Kluth M, Buscheck F, et al. High prevalence of p16 staining in malignant tumors. PLoS ONE. 2022;17(7):e0262877.","journal-title":"PLoS ONE"},{"issue":"7","key":"1542_CR24","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/his.14324","volume":"78","author":"DB Chapel","year":"2021","unstructured":"Chapel DB, Dubuc AM, Hornick JL, Sholl LM. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma. Histopathology. 2021;78(7):1032\u201342.","journal-title":"Histopathology"},{"issue":"1","key":"1542_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10014-022-00447-0","volume":"40","author":"L Lou","year":"2023","unstructured":"Lou L, Li J, Qin M, Tian X, Guo W, Li Y. Correlation of MTAP immunohistochemical deficiency with CDKN2A homozygous deletion and clinicopathological features in pleomorphic xanthoastrocytoma. Brain Tumor Pathol. 2023;40(1):15\u201325.","journal-title":"Brain Tumor Pathol"},{"issue":"2","key":"1542_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnen\/nlab127","volume":"81","author":"S Sasaki","year":"2022","unstructured":"Sasaki S, Takeda M, Hirose T, Fujii T, Itami H, Uchiyama T, et al. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study. J Neuropathol Exp Neurol. 2022;81(2):117\u201326.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1542_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cncy.21928","volume":"126","author":"Y Kinoshita","year":"2018","unstructured":"Kinoshita Y, Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, et al. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. Cancer Cytopathol. 2018;126(1):54\u201363.","journal-title":"Cancer Cytopathol"},{"key":"1542_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","volume":"104","author":"T Hida","year":"2017","unstructured":"Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, et al. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer. 2017;104:98\u2013105.","journal-title":"Lung Cancer"},{"issue":"2","key":"1542_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41379-019-0371-0","volume":"33","author":"S Brich","year":"2020","unstructured":"Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, et al. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. Mod Pathol. 2020;33(2):217\u201327.","journal-title":"Mod Pathol"},{"issue":"1","key":"1542_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/his.13872","volume":"75","author":"M Hamasaki","year":"2019","unstructured":"Hamasaki M, Kinoshita Y, Yoshimura M, Matsumoto S, Kamei T, Hiroshima K, et al. Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma. Histopathology. 2019;75(1):153\u20135.","journal-title":"Histopathology"},{"issue":"2","key":"1542_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","volume":"33","author":"DB Chapel","year":"2020","unstructured":"Chapel DB, Schulte JJ, Berg K, Churg A, Dacic S, Fitzpatrick C, et al. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol. 2020;33(2):245\u201354.","journal-title":"Mod Pathol"},{"issue":"4","key":"1542_CR32","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41379-020-00701-w","volume":"34","author":"K Satomi","year":"2021","unstructured":"Satomi K, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Narita Y, et al. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod Pathol. 2021;34(4):688\u2013700.","journal-title":"Mod Pathol"},{"issue":"6","key":"1542_CR33","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jid.2016.01.028","volume":"136","author":"WJ Woollard","year":"2016","unstructured":"Woollard WJ, Kalaivani NP, Jones CL, Roper C, Tung L, Lee JJ, et al. Independent Loss of Methylthioadenosine Phosphorylase (MTAP) in Primary Cutaneous T-Cell Lymphoma. J Invest Dermatol. 2016;136(6):1238\u201346.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1542_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/carcin\/bgi201","volume":"27","author":"C Hellerbrand","year":"2006","unstructured":"Hellerbrand C, Muhlbauer M, Wallner S, Schuierer M, Behrmann I, Bataille F, et al. Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis. 2006;27(1):64\u201372.","journal-title":"Carcinogenesis"},{"key":"1542_CR35","doi-asserted-by":"publisher","first-page":"107963","DOI":"10.1016\/j.lungcan.2024.107963","volume":"197","author":"MM Brune","year":"2024","unstructured":"Brune MM, Savic Prince S, Vlajnic T, Chijioke O, Roma L, Konig D, et al. MTAP as an emerging biomarker in thoracic malignancies. Lung Cancer. 2024;197:107963.","journal-title":"Lung Cancer"},{"issue":"1","key":"1542_CR36","doi-asserted-by":"publisher","first-page":"105492","DOI":"10.1016\/j.jbc.2023.105492","volume":"300","author":"GT Bedard","year":"2024","unstructured":"Bedard GT, Gilaj N, Peregrina K, Brew I, Tosti E, Shaffer K, et al. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition. J Biol Chem. 2024;300(1):105492.","journal-title":"J Biol Chem"},{"issue":"1","key":"1542_CR37","doi-asserted-by":"publisher","first-page":"25581","DOI":"10.1038\/s41598-025-10157-0","volume":"15","author":"N Gorbokon","year":"2025","unstructured":"Gorbokon N, Teljuk K, Reiswich V, Lutz F, Rico SD, Luhr C, et al. MTAP deficiency is highly homogeneous in advanced, muscle-invasive urothelial carcinoma of the urinary bladder. Sci Rep. 2025;15(1):25581.","journal-title":"Sci Rep"},{"key":"1542_CR38","doi-asserted-by":"crossref","unstructured":"Gorbokon N, Teljuk K, Reiswich V, Lennartz M, Minner S, Simon R et al. Deficiency of MTAP Is Frequent and Mostly Homogeneous in Pancreatic Ductal Adenocarcinomas. Cancers (Basel). 2025;17(7):1205.","DOI":"10.3390\/cancers17071205"},{"issue":"12","key":"1542_CR39","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J El Rodon","year":"2024","unstructured":"Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, El Helali A, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with <\u2009em>MTAP-deleted solid tumors: results from phase I dose exploration\u2009<\u2009sup>\u2606. Ann Oncol. 2024;35(12):1138\u201347.","journal-title":"Ann Oncol"},{"issue":"10","key":"1542_CR40","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.jtho.2017.07.015","volume":"12","author":"C Li","year":"2017","unstructured":"Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, et al. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(10):1536\u201343.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1542_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12308-023-00531-0","volume":"16","author":"S Fernandez-Pol","year":"2023","unstructured":"Fernandez-Pol S, Ferreira CR, Manohar V, Sanches JA, Lage L, Pereira J, et al. Comparison of two immunohistochemical staining protocols for ALK demonstrates non-inferiority of a 5A4 clone-based protocol versus an ALK01 clone-based protocol for the diagnosis of ALK\u2009+\u2009anaplastic large cell lymphoma. J Hematop. 2023;16(1):1\u20135.","journal-title":"J Hematop"},{"issue":"3","key":"1542_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.humpath.2003.10.012","volume":"35","author":"SL Swierczynski","year":"2004","unstructured":"Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35(3):357\u201366.","journal-title":"Hum Pathol"},{"issue":"8","key":"1542_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/PAI.0b013e3182a7d16d","volume":"22","author":"MB Pedersen","year":"2014","unstructured":"Pedersen MB, Riber-Hansen R, Nielsen PS, Bendix K, Hamilton-Dutoit SJ, D\u2019Amore F, et al. Digital pathology for the validation of tissue microarrays in peripheral T-cell lymphomas. Appl Immunohistochem Mol Morphol. 2014;22(8):577\u201384.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"1542_CR44","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1016\/S0002-9440(10)63075-1","volume":"159","author":"J Torhorst","year":"2001","unstructured":"Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159(6):2249\u201356.","journal-title":"Am J Pathol"},{"issue":"1","key":"1542_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0165-4608(95)00157-3","volume":"86","author":"H Zhang","year":"1996","unstructured":"Zhang H, Chen ZH, Savarese TM. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet Cytogenet. 1996;86(1):22\u20138.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"1542_CR46","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021;12(1):5606.","journal-title":"Nat Commun"},{"issue":"18","key":"1542_CR47","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/onc.2010.614","volume":"30","author":"C Romagosa","year":"2011","unstructured":"Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, Castellvi J, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30(18):2087\u201397.","journal-title":"Oncogene"},{"issue":"4","key":"1542_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/00125480-200607000-00006","volume":"13","author":"AN Kalof","year":"2006","unstructured":"Kalof AN, Cooper K. p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv Anat Pathol. 2006;13(4):190\u20134.","journal-title":"Adv Anat Pathol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01542-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:09:31Z","timestamp":1782720571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01542-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1542"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01542-0","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of archived remnants of diagnostic tissues for manufacturing of TMAs and their analysis for research purposes as well as patient data analysis has been approved by local laws (HmbKHG, \u00a7\u00a012) and by the local ethics committee (Ethics commission Hamburg, WF-049\/09). All work has been carried out in compliance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The recombinant rabbit monoclonal antibodies, clones MSVA-741R and MSVA-016R were provided from MS Validated Antibodies GmbH, Hamburg, Germany (owned by a family member of GS).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}